Organization
Frontera Therapeutics
4 clinical trials
Clinical trial
An Open-label, Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intraocular Administration of FT-002 in Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa.Status: Recruiting, Estimated PCD: 2023-10-31
Clinical trial
An Open-label, Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FT-003 in Subjects With Neovascular Age-related Macular DegenerationStatus: Not yet recruiting, Estimated PCD: 2024-11-30
Clinical trial
An Open-label, Multy-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FT-003 in Subjects With Diabetic Macular EdemaStatus: Recruiting, Estimated PCD: 2025-05-01